Barclays
ACTU

Barclays’s Actuate Therapeutics ACTU Stock Holding History

Barclays’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.96K Sell
2,176
-12,770
-85% -$52.9K ﹤0.01% 4750
2025
Q4 		$91.5K Buy
14,946
+6,081
+69% +$41.8K ﹤0.01% 4608
2025
Q3 		$59.3K Sell
8,865
-28,469
-76% -$206K ﹤0.01% 4732
2025
Q2 		$228K Buy
+37,334
New +$326K ﹤0.01% 4194

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays's ACTU Position: Q1 2026 in Review

Barclays reduced its Actuate Therapeutics (ACTU) stake by 85% in Q1 2026, selling an estimated $52.9K and leaving 2,176 shares worth $5.96K. The position accounts for ﹤0.01% of the portfolio, ranked #4750.

Barclays first reported a position in ACTU in Q2 2025 and has held it in 4 quarters since. The position peaked at $228K in Q2 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • Barclays held 2,176 shares of Actuate Therapeutics worth $5.96K as of Q1 2026.
  • Barclays sold 12,770 Actuate Therapeutics shares in Q1 2026, an estimated $52.9K.
  • Actuate Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4750 holding.
  • Barclays first reported a position in Actuate Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Barclays's Actuate Therapeutics position peaked at $228K in Q2 2025.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.